NLS Historical Balance Sheet

NLSP Stock

USD 3.66 0.10 2.81%

Trend analysis of NLS Pharmaceutics AG balance sheet accounts such as Total Current Liabilities of 4.5 M provides information on NLS Pharmaceutics' total assets, liabilities, and equity, which is the actual value of NLS Pharmaceutics to its prevalent stockholders. By breaking down trends over time using NLS Pharmaceutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining NLS Pharmaceutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether NLS Pharmaceutics is a good buy for the upcoming year.

NLS Pharmaceutics Inventory

(38,974.64)

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

About NLS Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of NLS Pharmaceutics at a specified time, usually calculated after every quarter, six months, or one year. NLS Pharmaceutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of NLS Pharmaceutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which NLS currently owns. An asset can also be divided into two categories, current and non-current.

NLS Pharmaceutics Balance Sheet Chart

At this time, NLS Pharmaceutics' Total Current Assets are relatively stable compared to the past year. As of 11/27/2024, Common Stock is likely to grow to about 770.1 K, while Total Current Liabilities is likely to drop slightly above 4.5 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Net Working Capital

Total Assets

Total assets refers to the total amount of NLS Pharmaceutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in NLS Pharmaceutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on NLS Pharmaceutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of NLS Pharmaceutics AG are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from NLS Pharmaceutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into NLS Pharmaceutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

	2021	2023	2024 (projected)
Short and Long Term Debt Total	1.6M	1.5M	1.4M
Total Assets	5.8M	1.8M	3.3M

Short Long Term Debt Total Total Assets

NLS Pharmaceutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital
Total Assets		-0.33	0.08	-0.04	0.89	0.38	0.66	-0.78	-0.46	0.07	0.96	-0.25	-0.25	-0.34	-0.33	0.96	-0.18	0.19	0.22	-0.34	0.14	0.62	-0.63	0.42	0.99	0.61
Short Long Term Debt Total	-0.33		-0.82	-0.81	-0.4	-0.97	-0.73	0.84	0.82	-0.87	-0.13	-0.4	-0.37	-0.28	1.0	-0.13	0.69	-0.9	-0.5	0.99	-0.55	-0.82	0.67	0.66	-0.26	0.45
Other Current Liab	0.08	-0.82		0.99	0.03	0.85	0.55	-0.56	-0.8	0.99	-0.11	0.52	0.51	0.0	-0.83	-0.11	-0.66	0.92	0.56	-0.83	0.61	0.76	-0.15	-0.79	0.02	-0.68
Total Current Liabilities	-0.04	-0.81	0.99		-0.05	0.83	0.47	-0.49	-0.73	0.99	-0.23	0.59	0.58	0.09	-0.83	-0.23	-0.65	0.9	0.5	-0.82	0.57	0.68	-0.13	-0.86	-0.11	-0.76
Total Stockholder Equity	0.89	-0.4	0.03	-0.05		0.45	0.55	-0.82	-0.31	0.06	0.92	-0.15	-0.17	-0.02	-0.39	0.92	-0.14	0.17	-0.03	-0.42	-0.09	0.57	-0.73	0.42	0.89	0.63
Other Liab	0.38	-0.97	0.85	0.83	0.45		0.73	-0.86	-0.8	0.89	0.22	0.42	0.4	0.21	-0.97	0.22	-0.6	0.9	0.44	-0.97	0.49	0.86	-0.57	-0.59	0.31	-0.37
Net Tangible Assets	0.66	-0.73	0.55	0.47	0.55	0.73		-0.82	-0.92	0.56	0.49	-0.24	-0.25	-0.14	-0.72	0.49	-0.68	0.78	0.79	-0.72	0.78	0.91	-0.67	-0.26	0.66	-0.03
Net Debt	-0.78	0.84	-0.56	-0.49	-0.82	-0.86	-0.82		0.74	-0.58	-0.65	-0.14	-0.11	-0.05	0.84	-0.65	0.52	-0.67	-0.36	0.84	-0.35	-0.87	0.81	0.15	-0.73	-0.1
Retained Earnings	-0.46	0.82	-0.8	-0.73	-0.31	-0.8	-0.92	0.74		-0.79	-0.24	0.0	0.01	0.13	0.82	-0.24	0.81	-0.92	-0.86	0.81	-0.86	-0.93	0.5	0.54	-0.44	0.35
Accounts Payable	0.07	-0.87	0.99	0.99	0.06	0.89	0.56	-0.58	-0.79		-0.12	0.55	0.53	0.1	-0.88	-0.12	-0.66	0.94	0.53	-0.87	0.59	0.75	-0.22	-0.82	0.0	-0.69
Cash	0.96	-0.13	-0.11	-0.23	0.92	0.22	0.49	-0.65	-0.24	-0.12		-0.32	-0.32	-0.31	-0.14	1.0	0.01	-0.01	0.01	-0.15	-0.09	0.47	-0.52	0.62	0.97	0.78
Non Current Assets Total	-0.25	-0.4	0.52	0.59	-0.15	0.42	-0.24	-0.14	0.0	0.55	-0.32		1.0	0.18	-0.43	-0.32	-0.02	0.25	-0.32	-0.42	-0.21	0.0	0.07	-0.54	-0.35	-0.56
Non Currrent Assets Other	-0.25	-0.37	0.51	0.58	-0.17	0.4	-0.25	-0.11	0.01	0.53	-0.32	1.0		0.14	-0.4	-0.32	0.01	0.23	-0.32	-0.39	-0.21	-0.01	0.1	-0.53	-0.35	-0.55
Other Assets	-0.34	-0.28	0.0	0.09	-0.02	0.21	-0.14	-0.05	0.13	0.1	-0.31	0.18	0.14		-0.24	-0.31	0.1	0.09	-0.19	-0.24	-0.19	-0.1	-0.27	-0.29	-0.34	-0.23
Long Term Debt	-0.33	1.0	-0.83	-0.83	-0.39	-0.97	-0.72	0.84	0.82	-0.88	-0.14	-0.43	-0.4	-0.24		-0.14	0.71	-0.9	-0.49	1.0	-0.54	-0.82	0.66	0.66	-0.26	0.46
Cash And Short Term Investments	0.96	-0.13	-0.11	-0.23	0.92	0.22	0.49	-0.65	-0.24	-0.12	1.0	-0.32	-0.32	-0.31	-0.14		0.01	-0.01	0.01	-0.15	-0.09	0.47	-0.52	0.62	0.97	0.78
Net Receivables	-0.18	0.69	-0.66	-0.65	-0.14	-0.6	-0.68	0.52	0.81	-0.66	0.01	-0.02	0.01	0.1	0.71	0.01		-0.78	-0.69	0.73	-0.71	-0.72	0.45	0.57	-0.16	0.45
Common Stock Total Equity	0.19	-0.9	0.92	0.9	0.17	0.9	0.78	-0.67	-0.92	0.94	-0.01	0.25	0.23	0.09	-0.9	-0.01	-0.78		0.73	-0.89	0.78	0.87	-0.39	-0.75	0.15	-0.58
Common Stock Shares Outstanding	0.22	-0.5	0.56	0.5	-0.03	0.44	0.79	-0.36	-0.86	0.53	0.01	-0.32	-0.32	-0.19	-0.49	0.01	-0.69	0.73		-0.46	0.98	0.68	-0.25	-0.49	0.23	-0.38
Non Current Liabilities Total	-0.34	0.99	-0.83	-0.82	-0.42	-0.97	-0.72	0.84	0.81	-0.87	-0.15	-0.42	-0.39	-0.24	1.0	-0.15	0.73	-0.89	-0.46		-0.51	-0.83	0.66	0.64	-0.27	0.44
Other Current Assets	0.14	-0.55	0.61	0.57	-0.09	0.49	0.78	-0.35	-0.86	0.59	-0.09	-0.21	-0.21	-0.19	-0.54	-0.09	-0.71	0.78	0.98	-0.51		0.66	-0.23	-0.59	0.14	-0.48
Other Stockholder Equity	0.62	-0.82	0.76	0.68	0.57	0.86	0.91	-0.87	-0.93	0.75	0.47	0.0	-0.01	-0.1	-0.82	0.47	-0.72	0.87	0.68	-0.83	0.66		-0.55	-0.34	0.59	-0.13
Total Liab	-0.63	0.67	-0.15	-0.13	-0.73	-0.57	-0.67	0.81	0.5	-0.22	-0.52	0.07	0.1	-0.27	0.66	-0.52	0.45	-0.39	-0.25	0.66	-0.23	-0.55		0.05	-0.61	-0.18
Net Invested Capital	0.42	0.66	-0.79	-0.86	0.42	-0.59	-0.26	0.15	0.54	-0.82	0.62	-0.54	-0.53	-0.29	0.66	0.62	0.57	-0.75	-0.49	0.64	-0.59	-0.34	0.05		0.48	0.96
Total Current Assets	0.99	-0.26	0.02	-0.11	0.89	0.31	0.66	-0.73	-0.44	0.0	0.97	-0.35	-0.35	-0.34	-0.26	0.97	-0.16	0.15	0.23	-0.27	0.14	0.59	-0.61	0.48		0.66
Net Working Capital	0.61	0.45	-0.68	-0.76	0.63	-0.37	-0.03	-0.1	0.35	-0.69	0.78	-0.56	-0.55	-0.23	0.46	0.78	0.45	-0.58	-0.38	0.44	-0.48	-0.13	-0.18	0.96	0.66

Click cells to compare fundamentals

NLS Pharmaceutics Account Relationship Matchups

NLS Pharmaceutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	696.4K	1.2M	5.8M	9.3M	1.8M	3.3M
Short Long Term Debt Total	7.1M	842.1K	2.1M	1.6M	1.5M	1.4M
Other Current Liab	835.7K	1.4M	666.4K	986.4K	1.7M	1.0M
Total Current Liabilities	4.0M	7.2M	2.4M	3.4M	7.9M	4.5M
Total Stockholder Equity	(6.2M)	(9.0M)	542.4K	3.3M	(8.8M)	(9.3M)
Other Liab	159.0K	2.7M	2.7M	2.8M	3.2M	1.9M
Net Tangible Assets	(8.8M)	(6.2M)	(9.0M)	542.4K	623.7K	654.9K
Net Debt	621.9K	2.0M	(5.4M)	(8.9M)	736.1K	772.9K
Retained Earnings	(26.9M)	(29.8M)	(41.7M)	(58.2M)	(70.4M)	(66.9M)
Accounts Payable	2.5M	4.0M	1.7M	2.4M	4.6M	2.7M
Cash	220.3K	93.7K	5.4M	8.9M	897.7K	852.8K
Non Current Assets Total	314.7K	1.0M	41.6K	30.2K	23.6K	22.4K
Non Currrent Assets Other	260.2K	946.9K	12.0K	12.1K	16.9K	16.0K
Cash And Short Term Investments	220.3K	93.7K	5.4M	8.9M	897.7K	852.8K
Net Receivables	75.4K	61.2K	38.6K	41.2K	10.7K	10.1K
Common Stock Shares Outstanding	11.1M	4.8M	14.7M	19.7M	38.2M	40.1M
Liabilities And Stockholders Equity	696.4K	1.2M	5.8M	9.3M	1.8M	3.3M
Non Current Liabilities Total	2.8M	3.0M	2.8M	2.6M	2.8M	3.4M
Other Current Assets	86.1K	14.4K	292.0K	191.0K	914.7K	960.5K
Other Stockholder Equity	20.6M	20.6M	42.1M	60.9M	61.0M	35.5M
Total Liab	6.9M	10.2M	5.2M	6.0M	10.7M	6.6M
Net Invested Capital	(5.3M)	(6.9M)	542.4K	3.3M	(7.2M)	(6.8M)
Total Current Assets	381.7K	196.7K	5.7M	9.2M	1.8M	3.1M
Accumulated Other Comprehensive Income	(18.7K)	(19.4K)	(151.7K)	(50.8K)	(158.1K)	(150.2K)
Net Working Capital	(3.7M)	(7.0M)	3.3M	5.9M	(6.1M)	(5.8M)
Inventory	(33.6K)	(61.2K)	(38.6K)	(41.2K)	(37.1K)	(39.0K)
Short Term Debt	690.1K	1.8M	2.5B	1.6M	1.9M	1.8M

Pair Trading with NLS Pharmaceutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NLS Pharmaceutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NLS Pharmaceutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with NLS Stock

0.77	FDMT	4D Molecular Therapeutics	Pair Corr
0.79	JNJ	Johnson Johnson Sell-off Trend	Pair Corr
0.91	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr

Moving against NLS Stock

0.85	BMY	Bristol Myers Squibb Sell-off Trend	Pair Corr
0.76	NAMS	NewAmsterdam Pharma	Pair Corr
0.59	PHVS	Pharvaris BV	Pair Corr
0.49	PMVP	Pmv Pharmaceuticals	Pair Corr
0.44	ESLAW	Estrella Immunopharma	Pair Corr

The ability to find closely correlated positions to NLS Pharmaceutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NLS Pharmaceutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NLS Pharmaceutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NLS Pharmaceutics AG to buy it.

The correlation of NLS Pharmaceutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NLS Pharmaceutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NLS Pharmaceutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for NLS Pharmaceutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for NLS Stock Analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NLS Historical Balance Sheet

NLS Pharmaceutics Inventory

(38,974.64)

About NLS Balance Sheet Analysis

NLS Pharmaceutics Balance Sheet Chart

Total Assets

Total Current Liabilities

NLS Pharmaceutics balance sheet Correlations

NLS Pharmaceutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

NLS Pharmaceutics balance sheet Accounts

Pair Trading with NLS Pharmaceutics

Moving together with NLS Stock

Moving against NLS Stock

Additional Tools for NLS Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Long Term Debt	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 1.0	Cash
Non Currrent Assets Other	+ 1.0	Non Current Assets Total
Non Current Liabilities Total	+ 1.0	Long Term Debt
Total Current Assets	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total

Non Current Liabilities Total	- 0.97	Other Liab
Long Term Debt	- 0.97	Other Liab
Other Liab	- 0.97	Short Long Term Debt Total
Other Stockholder Equity	- 0.93	Retained Earnings
Common Stock Total Equity	- 0.92	Retained Earnings
Retained Earnings	- 0.92	Net Tangible Assets